Repurposing, finding new uses for already approved drugs, has long been viewed as a way bring needed therapies to rare disease patients that’s fast and cost-effective. Pharnext is putting a new twist on repurposing by using genomic data and network pharmacology to identify thousands of molecules that may be involved in a disease and finding synergistic combinations of available therapies to treat it. We spoke to Daniel Cohen, CEO of Pharnext, about its so-called Pleotherapy, how it goes about finding and formulating combinations of drugs, and why this may hold greater promise than traditional repurposing approaches.

1 thought on “Pharnext Takes a Unique Twist on Repurposing Drugs for Rare Diseases”

  1. Andi Creed says:

    CVID Zebra here!

    Excellent idea!

Comments are closed.